TLC178

Taiwan Liposome Company · Phase 1 active Small molecule

At a glance

Generic name	TLC178
Also known as	Liposomal Vinorelbine
Sponsor	Taiwan Liposome Company
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Dose-escalation Study of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TLC178 CI brief — competitive landscape report
TLC178 updates RSS · CI watch RSS
Taiwan Liposome Company portfolio CI